**Provider Reimbursement Notice**

**Outpatient Hospital Infusion of Remdesivir**

**OHCA PRN 2020-11**

December 14, 2020

**Dear Hospital Administrators,**

**Outpatient Hospital Infusion of Remdesivir**

Effective December 14, 2020, the Oklahoma Health Care Authority will allow separate reimbursement for outpatient hospital infusion of Veklury® (remdesivir) outside the Outpatient Prospective Payment System (OPPS) payment methodology when a SoonerCare member is considered to have moderate to severe COVID, but the treating hospital physician deems the patient stable enough to be at home and able to come daily for treatment with Veklury® (remdesivir).

Separate reimbursement will be allowed for the following code for Veklury® (remdesivir):

* S5001 (prescription drug, brand name)

Separate reimbursement for Veklury® (remdesivir) will only be paid in the hospital outpatient setting. Bill revenue code 636 with procedure code S5001 and the appropriate National Drug Code (NDC) for remdesivir on a separate outpatient hospital claim with no other procedure codes included. A copy of the purchase invoice and an infusion note must be attached to the claim. Claim will suspend for manual pricing.

If you have any questions or require additional information please contact Provider Reimbursement by email at [ProvReimb@okhca.org](mailto:ProvReimb@okhca.org).

Thank you for your continued service to Oklahoma’s SoonerCare members.